- Adverum Biotechnologies (NASDAQ:ADVM) announces new long-term data from the OPTIC clinical trial of ADVM-022 single intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their neovascular or wet age-related macular degeneration (wet AMD).
- Durable expression of aflibercept following a single, in-office IVT injection of ADVM-022, for both doses (2 x 10^11 vg/eye and 6 x 10^11 vg/eye).
- Majority of patients are supplemental anti-VEGF injection free. 60% and 87% of patients were injection free following 2 and 6 x 10^11 vg/eye dose, respectively. 73% of patients required zero or one injection.
- Substantial reduction in annualized anti-VEGF injection frequency was seen following ADVM-022 in patients who previously required frequent injections. 85% reduction for 2 x 10^11 vg/eye and 96% reduction for 6 x 10^11 vg/eye.
- Robust sustained aflibercept expression levels within therapeutic range was observed for both doses and reaching the top of the dose response curve.
- All ADVM-022-related ocular adverse events (AE) were mild to moderate and Inflammation when observed was mild and responsive to steroid eye drops.
- The data are being presented at ARVO 2021 Meeting.
- Recently, the company provided an update on ADVM-022 trial in diabetic macular edema.